 Vertex Pharmaceuticals Incorporated NASDAQ: VRTX and Verve Therapeutics Inc NASDAQ: VERV announced an exclusive, four-year global research collaboration to discover and develop an in vivo gene editing program for undisclosed liver disease. Under the terms of. 